MSA安全公司

最新新闻

• 评级变动
  Baird Maintains MSA Safety(MSA.US) With Hold Rating, Raises Target Price to $215
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 公司公告
  MSA Safety | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Vartanian Nishan J.
  SEC · 2024/3/15
• 评级变动
  B. Riley Securities Downgrades MSA Safety(MSA.US) to Hold Rating, Cuts Target Price to $195
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  B. Riley Downgrades MSA Safety to Neutral From Buy, Adjusts Price Target to $195 From $210
  MT Newswires · 2026/8/3
• 评级变动
  Baird Maintains MSA Safety(MSA.US) With Hold Rating, Raises Target Price to $197
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 公司公告
  MSA Safety | 4: Statement of changes in beneficial ownership of securities-Officer Vartanian Nishan J.
  SEC · 2024/3/15
• 评级变动
  J.P. Morgan Maintains MSA Safety(MSA.US) With Hold Rating, Raises Target Price to $220
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• J.P. Morgan Sticks to Their Hold Rating for MSA Safety (MSA)
  TipRanks · 2026/8/21
• 评级变动
  Stifel Maintains MSA Safety(MSA.US) With Hold Rating, Raises Target Price to $206
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  William Blair Maintains MSA Safety(MSA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• 评级变动
  Stifel Maintains MSA Safety(MSA.US) With Hold Rating, Maintains Target Price $202
  \u5e02\u573a\u8d44\u8baf · 2026/8/1
• Huafeng Technology (688629.SH): Actively participates in the OPEN NPO MSA alliance and actively carries out R&D and technical reserves for high-speed interconnect supporting products centered on the NPO architecture.
  Gelonghui Finance · 2026/9/21
• 公司公告
  Talius Group Ltd: Talius Signs MSA with Inturai Ventures Corp.
  ASX · 2026/7/1
• 评级变动
  D.A. Davidson Maintains MSA Safety(MSA.US) With Buy Rating, Cuts Target Price to $206
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 公司公告
  Daito Pharmaceutical: Collaboration between Nobel Pharma Co., Ltd. and Daito Co., Ltd. for the development of NPC-29 (ubiquinol-containing formulation with multiple system atrophy (MSA) as an indication)
  JPX · 2025/1/15
• J.P. Morgan Maintains MSA Safety(MSA.US) With Hold Rating, Maintains Target Price $220
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 公司公告
  Daito Pharmaceutical: Nobel Pharma Co., Ltd. and Daito Co., Ltd. signed a basic development agreement for NPC-29 (ubiquinol-containing formulation with multiple system atrophy (MSA) as an indication)
  JPX · 2025/5/29
• 评级变动
  William Blair Maintains MSA Safety(MSA.US) With Buy Rating, Announces Target Price $225
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• MSA Safety(MSA.US) Director Sells US$3.88 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• Stifel Maintains MSA Safety(MSA.US) With Hold Rating, Maintains Target Price $206
  \u5e02\u573a\u8d44\u8baf · 2026/9/21

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。